Gautam Borthakur, M.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Borthakur
Dr. Borthakur is a Professor in the Department of Leukemia since 2018. His clinical and research work is focused on improving therapies for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). His primary commitment is to bring new agents/combinations to the clinic for improving outcome in patients with these diseases. He has particular interest in core binding factor leukemia. He has opened more than thirty investigator-initiated or industry-sponsored clinical trials in his area of interest and has an active translational research program on autophagy, mitochondrial dynamics, kinase inhibition (ERK 1/2) and epigenetic targets, for example BRD4 in AML.
Present Title & Affiliation
Primary Appointment
Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1984 | Assam Medical College, Dibrugarh, IND, MBBS, Medicine |
| 1979 | Cotton College, Guwahati University, Assam, IND, BS, Biology |
Postgraduate Training
| 2004-2005 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX |
| 2001-2004 | Clinical Fellowship, Hematology-Oncology, The University of Texas Health Science Center Houston and The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1993-1996 | Clinical Residency, Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY |
| 1987-1990 | Clinical Residency, Pathology, Post-Graduate Institute of Medical Education and Research, Chandigarh |
| 1985-1987 | House Officer, Internal Medicine, RML Hospital and GB Pant Hospital, New Delhi |
| 1985-1985 | Clinical Internship, Medicine, Assam Medical College, Dibrugarh |
Board Certifications
| 2004 | American Board of Internal Medicine-Hematology |
| 1996 | American Board of Internal Medicine |
| 1990 | National Academy of Medical Sciences (India)-Patho |
Experience & Service
Institutional Committee Activities
Member, Institutional Review Board 5, 2013 - Present
Selected Publications
Peer-Reviewed Articles
- Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma:1-6. e-Pub 2024. PMID: 38696743.
- Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica Online ahead of print(11):2853-2858, 2021. e-Pub 2021. PMID: 33054123.
- Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
- Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, Popovic R, Modi DA, Joshi RH, Wolff JE, Jonas BA. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer 127(16):2943-2953, 2021. e-Pub 2021. PMID: 33934351.
- Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J 11(6):114, 2021. e-Pub 2021. PMID: 34135311.
- Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer 127(8):1246-1259, 2021. e-Pub 2020. PMID: 33270904.
- Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2020. PMID: 32561839.
- Chen NC, Borthakur G, Pemmaraju N. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leuk Lymphoma 62(3):1-10, 2021. e-Pub 2020. PMID: 33161793.
- Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley GJ, Benhadji KA, DeAngelo DJ. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer 127(3):372-380, 2021. e-Pub 2020. PMID: 33107983.
- Siddiqui MT, Price A, Ferrajoli A, Borthakur G. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax. Leuk Res Rep 16:100266, 2021. e-Pub 2021. PMID: 34692401.
- Ball S, Borthakur G. Apoptosis targeted therapies in acute myeloid leukemia: an update. Expert Rev Hematol 13(12):1373-1386, 2020. e-Pub 2020. PMID: 33205684.
- Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33255818.
- Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol 95(11):1296-1303, 2020. e-Pub 2020. PMID: 32697348.
- Borthakur G. Evolving strategies for the management of core-binding factor acute myeloid leukemia. Clin Adv Hematol Oncol 18(11):691-694, 2020. PMID: 33406060.
- Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol 10:1538, 2020. e-Pub 2020. PMID: 32984009.
- Borthakur G. Prognosis interfered with by clonal interference. Blood 132(2):118-119, 2018. PMID: 30002046.
- Bhattacharya S, Piya S, Borthakur G. Bromodomain inhibitors: what does the future hold?. Clin Adv Hematol Oncol 16(7):504-515, 2018. PMID: 30067623.
- Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
- Abou Zahr A, Borthakur G. Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opin Emerg Drugs 22(2):137-148, 2017. e-Pub 2017. PMID: 28506135.
- Boddu P, Borthakur G. Therapeutic targeting of isocitrate dehydrogenase mutant AML. Expert Opin Investig Drugs 26(5):525-530, 2017. e-Pub 2017. PMID: 28388242.
- Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol 110:20-34, 2017. e-Pub 2016. PMID: 28109402.
- Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemo-resistance in Acute Myleogenous leukemia. Autophagy 13(1):0, 2017. e-Pub 2016. PMID: 27797294.
- Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood 128(9):1260-9, 2016. e-Pub 2016. PMID: 27268264.
- Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122(12):1871-9, 2016. e-Pub 2016. PMID: 26990290.
- Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Res. e-Pub 2016. PMID: 26822154.
- Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica 100(7):898-904, 2015. e-Pub 2015. PMID: 25887498.
- Owusu-Agyemang P, Borthakur G, Rebello E, Arunkumar R, Wang SA, Rytting M, Jorgensen JL, Hernandez M, Ruiz JR, Cata JP. The Association Between Opioid Administration and Response to Therapy in Patients with Acute Lymphoblastic Leukemia. Leuk Lymphoma 56(6):1-9, 2015. e-Pub 2015. PMID: 25363399.
- Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. Biomed Res Int 2015:497597, 2015. e-Pub 2015. PMID: 25654108.
- Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. PLoS One 10(10):e0139254, 2015. e-Pub 2015. PMID: 26440941.
- Arellano ML, Borthakur G, Berger M, Luer J, Raza A. A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Clin Lymphoma Myeloma Leuk 14(6):534-9, 2014. e-Pub 2014. PMID: 25052051.
- Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia. Am J Hematol 89(10):964-8, 2014. e-Pub 2014. PMID: 24990142.
- Shah DR, Daver N, Borthakur G, Hirsch-Ginsberg C, Oo TH. Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 14(4):e141-3, 2014. e-Pub 2014. PMID: 24630920.
- Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE. Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia. Protein Pept Lett 20(4):392-402, 2013. e-Pub 2012. PMID: 23016580.
- Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of Anti-CD33 Immunotoxin HUM-195/rGEL in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-21, 2013. e-Pub 2012. PMID: 22875630.
- Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular Granulocytic Sarcoma: A Case Report and Literature Review of Ocular Extramedullary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(1):93-6, 2013. e-Pub 2012. PMID: 23017332.
- Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett 329(1):45-58, 2013. e-Pub 2012. PMID: 23036488.
- Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, cyclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 2012. e-Pub 2012. PMID: 22360602.
- Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 2012. e-Pub 2012. PMID: 22228403.
- Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase 1 Study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 2011. e-Pub 2010. PMID: 20952518.
- Bryan J, Borthakur G. Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag 7:1-11, 2010. e-Pub 2010. PMID: 21339937.
- Samudio IJ, Duvvuri S, Clise-Dwyer K, Watt JC, Mak D, Kantarjian H, Yang D, Ruvolo V, Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma 51(5):911-9, 2010. PMID: 20423286.
- Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 2010. PMID: 20017599.
Other Articles
- Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G Spontaneous remission of acute myeloid leukemia: report of three patients and review of the literature. Clinical Leukemia 2(1):64-67, 2008.
Abstracts
- Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM,l Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. Blood 128(22), 2016.
- Piya S, Bhattacharya S, Mu H, Lorenzi PL, McQueen T, Davis ER, Ruvolo V, Baran N, Qian Y, Crews C, Kantarjian HM, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects. Blood 128(22), 2016.
- Borthakur G, Tallman MS, Ofran Y, Foran JM, Uy GL, DiPersio JF, Nagler A, Rowe JM, Showel MM, Altman J, Al-Rawi A, Wang R-Y, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig T, Aharon A, Bueso-Ramos CE, Cortes JE, Andreeff M. The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. Blood 128(22), 2016.
- Borthakur G, Tallman M, Ofran Y, Foran J, Uy G, DiPersio J, Nagler A, Rowe J, Showel M, Altman J, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig T, Aharon A, Bueso-Ramos C, Cortes J, Andreeff M. Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients. Clinical Lymphoma, Myeloma and Leukemia 16(2):S28, 2016.
- Ohanian M, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Alvarado Y, Konopleva M, Lim M, Pierce S, O'Brien SM, Ashizawa AT, Verstovsek S, Wierda WG, Cortes JE. Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies. J Clin Oncol 34(suppl), 2016.
- Borthakur G, Ofran Y, Nagler A, Rowe JM, Foran JM, Uy GL, DiPersio JF, Altman JK, Frankfurt O, Tallman MS, Peled A, Pereg Y, Vainstein A, Aharon A, Al Rawi A, McQueen T, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood 126(23), 2015.
- Borthakur G, Foran JM, Wang ES, Rakkar A, Minderman H, Burns J, Andreeff M, Tibes R,. A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine. Blood 126(23), 2015.
- Tamamyan G, Borthakur G, Cortes JE, Ravandi F, Jabbour E, Daver N, Pemmaraju N, Ohanian, Kolomansky A, Todisco G, Shi C, Pierce S, Peng SA, Konopleva M, Kantarjian HM, Kadia T. Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission. Blood 126(23), 2015.
- Borthakur G, Kantarjian H, O'Brien S, Garcia-Manero G, Jabbour E, Daver N, Kadia TM, Gborogen R, Konopleva M, Andreeff M, Ravandi F, Cortes J. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood 124(21):388, 2014.
- Kadia T, Borthakur G, Ferrajoli A, Daver N, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda WG, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood 124(21):3671, 2014.
Book Chapters
- Borthakur G, Estey EE. Therapy of acute myelogenous leukemia in adults. In: Cancer Treat Res, 257-71, 2010.
- Jabbour E, Borthakur G, Bueso-Ramos C, Kantarjian H, Faderl S. Acute Lymphoblastic Leukemia. In: MD Anderson Manual of Medical Oncology. McGraw-Hill Medical Publishing Division: United States, 3-17, 2006.
- Borthakur G, Bueso-Ramos C, O'Brien S. Chronic Lymphocytic Leukemia and Associated Disorders. In: MD Anderson Manual of Medical Oncology. McGraw-Hill Medical Publishing Division: United States, 39-55, 2006.
Grant & Contract Support
| Title: | PA16-0956: Study of Expression of IL1RAP in Leukemia Samples |
| Funding Source: | Cantargia AB |
| Role: | Co-Principal Investigator |
| Title: | 2016-0556 A phase 1/2, open-label, dose-escalation/dose-expansion, safety and tolerability study of INCB059872 in subjects with advanced malignancies |
| Funding Source: | Incyte Corporation |
| Role: | Principal Investigator |
| Title: | 2017-0092: A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in combination with Low Dose Cytarabine in Subjects with Newly-diagnosed Acute Myeloid Leukemia |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator |
| Title: | BRD4 Protein Targeting Chimera (PROTAC) as Therapeutic Option in T Acute Lymphoblastic Leukemia |
| Funding Source: | MDACC Institutional Research Grant |
| Role: | Principal Investigator |
| Title: | 2015-0665: Phase 1 A/B Study of LY2606368 in Combination with Cytarabine and Fludarabine in Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) |
| Funding Source: | Eli Lilly and Company |
| Role: | Principal Investigator |
| Title: | Concomitant targeting of stroma and leukemia to overcome resistance in acute myeloid leukemia associated with FLT3 mutations |
| Funding Source: | Children's Leukemia Research Association, Inc |
| Role: | Principal Investigator |
| Title: | 2018-0549 A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes |
| Funding Source: | Cyclacel, Inc |
| Role: | Principal Investigator |
| Title: | 2016-0889 An Open-label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome |
| Funding Source: | Janssen Scientific Affairs, LLC |
| Role: | Principal Investigator |
| Title: | Anti-leukemic effect of BRD4 Proteolysis Targeting Chimera (PROTAC); ARV-825 and ARV-771 in preclinical model of disseminated acute myelogenous leukemia in mouse |
| Funding Source: | Arvinas, Inc |
| Role: | Principal Investigator |
| Title: | 2018-0319 A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy |
| Funding Source: | AstraZeneca |
| Role: | Principal Investigator |
| Title: | Therapy of AML (overall) Project 4:Clinical Trials in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | 2013-0527: A phase I/II open-label,dose escalation study to investigate the safety,PK, PD & clinical activity of GSK525762 in subjects with relapsed,refractory hematologic malignancies |
| Funding Source: | GlaxoSmithKline |
| Role: | Principal Investigator |
| Title: | 2012-1097: A Phase 1/2, Multicenter, Open-label Study Designed to Evaluate Safety and Efficacy Profile of Repeated Escalating Doses of BL-8040 in Adult Subjects with Relapsed Acute Myeloid Leukemia |
| Funding Source: | Bioline |
| Role: | Principal Investigator |
| Title: | LS2012-36679: Study of activity of E6201, a dual FLT3 and MEK inhibitor, in acute myelogenous leukemia with FLT or RAS mutation |
| Funding Source: | Eisai |
| Role: | Principal Investigator |
| Title: | 2016-0401 A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects with relapsed/refractory acute myeloid leukemia |
| Funding Source: | GlaxoSmithKline |
| Role: | Principal Investigator |
| Title: | 2011-0319: Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML) |
| Funding Source: | Novartis |
| Role: | Principal Investigator |